BioInvent International
29,5
SEK
+3,15 %
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
+3,15%
-23,38%
-24,16%
-31,79%
-31,95%
+77,5%
-24,09%
-13,22%
-96,91%
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Læs mereMarkedsværdi
1,94 mia. SEK
Aktieomsætning
1,12 mio. SEK
Omsætning
71,46 mio.
EBIT %
-517,69 %
P/E
-
Udbytteafkast, %
-
Finanskalender
27.2
2025
Årsrapport '24
29.4
2025
Generalforsamling '25
29.4
2025
Delårsrapport Q1'25
ViserAlle indholdstyper
BioInvent International AB: BioStock: BioInvent kicks off 2025 with positive clinical data
BioInvent announces promising initial efficacy data from triple combination arm of BI-1206, rituximab and Calquence for the treatment of non-Hodgkin's lymphoma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools